library.onepin.app/gnrh-gonadorelin Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider
Hormonal FDA-approved medicine

GnRH (Gonadorelin)

Gonadorelin · GnRH · Lutrelef · Cystorelin · Factrel

100-200mcg – 100-200 mcg SubQ 2-3x/week

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. It binds to GnRH receptors on the anterior pituitary gland, stimulating the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These gonadotropins are essential for reproductive function, stimulating testosterone production in males and ovulation in females.

Quick Start
Route
Subcutaneous (SubQ)
Start low
100-200mcg SubQ
Frequency
2-3x/week
Timing
No specific requirement

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Conservative start
100-200mcg · Subcutaneous (SubQ) · 2-3x/week
conservative starter
100-200mcg
2-3x/week
Intermediate
Pulsatile HPTA Stimulation
100-200 mcg · SubQ · 2x Weekly
human clinical trial · FDA Factrel label
Used heavily by TRT clinics as an alternative to HCG for testicular preservation, though its short half-life makes twice-weekly dosing highly controversial for sustained efficacy.
100-200 mcg
2x Weekly
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Binds to GnRH receptors on anterior pituitary gonadotroph cells, activating phospholipase C signaling cascade, which triggers the release of stored LH and FSH into the bloodstream.

Pulsatile administration maintains receptor sensitivity and mimics physiological GnRH secretion patterns, sustaining gonadotropin output. Continuous exposure causes receptor downregulation and paradoxical suppression.

Downstream effects include stimulation of Leydig cells (testosterone production) and Sertoli cells (spermatogenesis) in males, and follicular development and ovulation in females.

02

What to expect

Early
Days 1–7

Days 1-7: Acute LH/FSH pulses occur within minutes of each injection. No subjective effects typically noticed.

03

Evidence

HumanPresent
AnimalStrong
In-vitroPresent

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 100-200mcg; Subcutaneous (SubQ); 2-3x/week. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.

Mechanism: Binds to GnRH receptors on anterior pituitary gonadotroph cells, activating phospholipase C signaling cascade, which triggers the release of stored LH and FSH into the bloodstream.. No checked live PubMed abstract provided an exact-molecule/formulation sentence supporting this source-JSON mechanism claim.

Primary safety claim: Injection site reactions (redness, swelling, mild pain). No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.

04

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

AnastrozoleAI manages estradiol from gonadorelin-stimulated testosterone production - no direct interaction
DHEANo pharmacological conflict - DHEA provides adrenal androgen support independent of GnRH axis
KisspeptinKisspeptin is upstream of GnRH release - concurrent use may be redundant but not harmful
Injectable B-ComplexNo interaction - administer in separate syringes

Keep separate

Triptorelin (continuous)Continuous GnRH agonist exposure causes receptor downregulation and HPG axis suppression - opposes gonadorelin's purpose of maintaining pulsatile stimulation
Any compound in same syringeGonadorelin is a fragile peptide that should be administered alone - do not mix in the same syringe with other peptides

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

05

Pharmacokinetics

Illustrative plasma concentration · 0.5 h
Half-life
~2-4 min
Peak · Tmax
~10-20 min

SubQ

Elimination
~15-30 min
Bioavailability
~100%

SubQ/IV

Duration of action
1-4 hours

LH/FSH pulse

Clearance

Enzymatic degradation (endopeptidases) and renal

Storage. Store refrigerated at 2-8C. Protect from light. Reconstituted solution stable for up to 14 days refrigerated.

06

Regulatory status

FDA-approved (Factrel, Lutrepulse) for diagnostic use and treatment of hypothalamic amenorrhea. Off-label use for fertility preservation during TRT.

Put it to work

Calculate, log & track

Open GnRH (Gonadorelin) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open GnRH (Gonadorelin) in the app →

Go deeper

The guide & community

The complete GnRH (Gonadorelin) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community

Track it in OnePin. Log vials, draws, and protocols in the app.